Cargando…
Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study
BACKGROUND: Current practices for assessing response to anti-interleukin 5/R treatment in severe asthma patients are heterogeneous. The objective of this study was to achieve an expert consensus defining failure criteria for anti-interleukin 5/R treatment in severe asthma patients. METHODS: Experts...
Autores principales: | Mattei, Laura, Suehs, Carey M., Alagha, Khuder, Bourdin, Arnaud, Brousse, Christophe, Charriot, Jeremy, Devouassoux, Gilles, Fry, Stephanie, Guilleminault, Laurent, Gouitaa, Marion, Taille, Camille, Chanez, Pascal, Pahus, Laurie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504226/ https://www.ncbi.nlm.nih.gov/pubmed/34629000 http://dx.doi.org/10.1177/17534666211049735 |
Ejemplares similares
-
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
por: Taillé, Camille, et al.
Publicado: (2020) -
Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study
por: Suehs, Carey Meredith, et al.
Publicado: (2020) -
Patient distrust in pharmaceutical companies: an explanation for women under-representation in respiratory clinical trials?
por: Pahus, Laurie, et al.
Publicado: (2020) -
Epithelial ciliated beating cells essential for ex vivo ALI culture growth
por: Gras, Delphine, et al.
Publicado: (2017) -
“Real-life” management of patients with severe asthma in the biologics era: Can we do better?()
por: Charriot, Jeremy, et al.
Publicado: (2021)